Clinical data
Routes of
ATC code none
Legal status
Legal status
  • Uncontrolled
Pharmacokinetic data
Metabolism Liver (CYP2D6)[1]
CAS Number 61337-87-9 YesY
PubChem (CID) 3085218
E. maleate: CID 6451144
DrugBank DB00316 N
ChemSpider 2342166 YesY
UNII 4685R51V7M YesY
KEGG D04055 YesY
ECHA InfoCard 100.056.994
Chemical and physical data
Formula C17H19N3
Molar mass 265.35 g/mol
3D model (Jmol) Interactive image
Melting point 114 to 116 °C (237 to 241 °F)
Solubility in water Soluble in methanol and chloroform mg/mL (20 °C)
 NYesY (what is this?)  (verify)

Esmirtazapine (ORG-50,081) is a drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause.[2][3][4][5] Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.[2][6] As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.[7]

See also


This article is issued from Wikipedia - version of the 9/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.